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ties can become useful option for selected patients with metastatic 
pulmonary tumors with keeping radicality and low-invasiveness. 
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Magnetic navigation system for thoracoscopic surgery of the lung 
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Background: Recent progress of computerized tomography (CT) 
offered a new alternative to detect micro-lesions in the respiratory 
system. Furthermore, the state-of-the-art positron emission tomogra-
phy offered a new opportunity to ﬁnd out the lung tumor in the very 
early stage. However, such ﬁne lesions are often too small to be found 
out under the video scope, and too soft to be distinguished with the 
surgeons’ ﬁnger touch. To solve this problem, we have developed a 
magnetic navigation system that could identify the location of a micro-
magnetic marker, which was embedded near or at the tumor site before 
surgery.
Methods: The magnetic navigation system we developed mainly 
consists of a powerful micro-magnetic transmitter made of very 
strong magnet, three micro-ﬂuxgate magnetic sensor probes forming a 
triangular prism, a 16-Bit A/D converter, a data analyzer, a down-scan 
converter, and an image monitor (see Fig. 1). The virtual image of the 
transmitter is then generated and superimposed on the endoscopic im-
age monitor through the down-scan converter in real-time. 
Image overlay: In order to make an accurate superposition of a magnet 
on the display, we used the direct projection matrix method using vir-
tual sample points inside the patient’s body. In this system, we can use 
any type of endoscopes with, either direct or oblique-viewing.
Protocol for clinical application: The patient received the right thora-
cotomy and a magnet was placed on the lung with transbronchial mark-
ing under CT guidance, and the set of the magnetic navigation system 
was settled down on the thoracic cavity. After the image injection 
calibration, the real location of the lesion including the small magnet at 
the vicinity of the tumor could be superimposed on the video monitor 
display 
Results: We could do the thoracoscopic surgery of the lung partial 
resection with our magnetic navigation system.
(1) Our magnetic navigation system could identify the real location 
of the lesion of the small magnet on the video monitor display and 
superimpose the real movement of the target on the display.
(2) We could take the magnetic marking lesion away under the guidance 
of our magnetic navigation system with the oblique-view scope.
Conclusions: Our magnetic navigation system may be very useful 
when the tumor lesions are too small to be found out where it is under 
the video-assisted thoracoscopy, and too soft to be distinguished with 
the surgeons’ ﬁnger touch. 
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Background: Partial lung resection is one of the most important and 
standard procedure for benign lung lesions and some malignant tumors. 
Several endoscopic staplers are required for partial lung resection in 
video-assisted thoracic surgery (VATS). When the lung is resected us-
ing the staplers that hold it, the lung parenchyma is often squeezed to 
the distal side of the stapler. Thus, another stapler has to be required for 
complete resection. Now, we have developed a new device for VATS. 
Method: A new device named “double-hook retractor (DHR)” com-
prises a sterilized disposable endotracheal ﬂexible stylet. (ﬁg.1) This 
device can be easily reshaped as the cutting line of the lung that is to 
be resected. When we performed partial lung resection by staplers, the 
staplers are ﬁred as usual so far as the lung that is to be resected leaves 
the width of lung tissue which another stapler will ﬁnish to resect. DHR 
is used for pushing the lung parenchyma to the proximal side of the 
stapler to prevent it from being squeezed away by the stapler when the 
lung is about to be resected by the last stapler. (ﬁg.2) 
Results: 5 patients underwent VATS partial resection with DHR (2 for 
indeterminate pulmonary nodule, 3 for metastatic lung tumor). The use 
of DHR succeeded in retracting the lung parenchyma by 8-10 mm to 
the proximal side of the stapler and reducing the number of staplers to 
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only 2 or less. Air leakage and bleeding from the stump didn’t occur in 
any of the patients. 
Conclusion: The reduction in the number of staplers used for VATS 
partial lung resection by DHR thus helped in improving the cost-ef-
fectiveness of the procedure. Further, the use of DHR didn’t cause any 
complications that arise due to the error of staplers. 
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Background: Cryoablation is one of the minimally invasive ablation 
modalities. We have performed percutaneous CT guided cryoablation 
under local anesthesia for local control of lung tumors. So far, in a little 
over 100 patients, we have had no major complications. In the present 
study, we report our preliminary experience in 2 cases of lung cancer 
found in the contralateral lung in postpneumonectomy patients. 
Case 1: 63 year old male. He had undergone right pneumonectomy for 
lung cancer 2 years previously. He was referred to us for metachronous 
primary lung cancer in the left upper lobe, cT1N0M0. Cryoablation 
was performed using two 2-mm probes, with adequate ablation mar-
gins. A small pneumothorax occurred after the procedure. Although the 
patient was symptom free, chest tube was inserted prophylactically. He 
was discharged 7 days post ablation.
Case 2: 59 year old female. She had undergone left pneumonectomy 
followed by chemotherapy for lung cancer 2 years previously. She was 
referred to us for suspected lung cancer metastasis in the right lower 
lobe. Cryoablation was performed using two 2-mm probes, with ad-
equate ablation margins. She was discharged 7 days post ablation.
Comments: Although the post-ablation observation period is still too 
short to evaluate local control, the cryoablation procedure was well 
tolerated in both patients. Cryoablation could become a less invasive 
alternative to partial resection under general anesthesia in postpnuemo-
nectomy patients for both metachronous primary lung cancer, and lung 
metastasis.
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Phase III randomized study of oral vinorelbine (oV) and 
gemcitabine (G) (oVG) versus docetaxel (D) and gemcitabine (DG) 
as first-line treatment of patients with advanced non-small cell lung 
cancer (NSCLC): A preliminary report
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Background: Non-platinum based doublets are effective treatments for 
advanced NSCLC. We performed a multicenter phase III trial to com-
pare the efﬁcacy and tolerance of oVG and DG in NSCLC patients (pts). 
Methods: Chemotherapy-naive pts with stage IIIB/IV NSCLC and PS 
(WHO) 0-2 and adequate organ function were eligible. Pts received oV 
70mg/m2 combined with G 900mg/m2 on days 1, 15 of a 4-week cycle 
or D 75mg/m2 on day 1 combined with G 1000mg/m2 on days 1, 8 of a 
3-week cycle. Primary endpoint was OS and secondary endpoints were 
response rate (RR), time to progression (TTP) and toxicity. Stratiﬁca-
tion was done for age, stage and PS. 
Results: 254 pts received oVG (n=121) or DG (n=133). Median age 
was 64 and 63 years, and PS was 0-1 in 94.2% and 94%, for oVG and 
DG, respectively. Most patients had disease stage IV and were ≤70 
years (80.9% vs 74.4% and 74% vs 77%, in oVG and DG, respective-
ly). After a median follow-up time of 6.1 months, median OS was 9.0 
vs 10.7 months and 1-yr survival was 38% vs 46% for oVG and DG, 
respectively (p=0.486). Signiﬁcantly more responders were observed 
in the DG arm (11% vs 23%, p=0.018). Median TTP was 3.1 vs 3.9 for 
oVG and DG, respectively (p=0.335). A similar toxicity proﬁle was 
observed except for a trend for higher neutropenia grade 3-4 in DG 
compared to oVG (p= 0.066). There was no difference with respect to 
neutropenic infections (p= 0.124). An analysis of the inﬂuence of age 
(≤70 and ≥ 70) on OS and toxicity revealed that OS was similar for 
both arms in the two age groups but grade 3-4 neutropenia was lower in 
the oVG arm for pts ≥70 years. 
Conclusions: A higher RR that was not translated to a survival beneﬁt 
was recorded for the DG arm. Both regimens were well tolerated with-
out signiﬁcant differences in toxicity. 
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Background: Concurrent chemoradiation (CCRT) is recommended as 
the evidence-based approach for the management of patients with stage 
IIIB non-small cell lung cancer (NSCLC) comprising 45% of initial 
